Core Viewpoint - InMed Pharmaceuticals will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York, where the management team will conduct one-on-one meetings with investors and present updates on their drug development pipeline [1][2]. Group 1: Company Overview - InMed Pharmaceuticals is focused on developing proprietary small molecule drug candidates targeting diseases with high unmet medical needs, including Alzheimer's, ocular, and dermatological conditions [3]. - The company's leading pharmaceutical program, INM-901, is aimed at treating Alzheimer's disease and has recently presented data at the Alzheimer's Association International Conference (AAIC) 2025 [2][3]. Group 2: Conference Details - The H.C. Wainwright 27th Annual Global Investment Conference will feature a corporate presentation from InMed, which will be available online for 90 days [3]. - The conference provides an opportunity for InMed's management to engage directly with investors through one-on-one meetings [1].

Core Viewpoint - Purepoint Uranium Group Inc. has successfully closed the final tranche of its private placement, raising a total of $6,000,137.79 to support uranium exploration in the Athabasca Basin, Saskatchewan [1][3]. Financing Details - The final tranche of the private placement included a combination of traditional flow-through units and SK and NT flow-through units, with a total issuance of 772,946 traditional units, 5,768,824 SK units, and 3,041,295 NT units [1][6]. - Each flow-through unit consists of one common share and one common share purchase warrant, with an exercise price of $0.50 per share for a period of 24 months [1]. Use of Proceeds - Proceeds from the private placement will be allocated for the exploration and advancement of the company's projects in the Athabasca Basin [3]. Related Party Transaction - IsoEnergy Ltd. acquired 2,531,646 SK flow-through units, which is classified as a related party transaction as IsoEnergy holds 10.6% of Purepoint's common shares prior to this acquisition [4]. - Following the private placement, IsoEnergy owns approximately 12.57% of Purepoint's issued and outstanding common shares on a non-diluted basis and approximately 18.65% on a partially diluted basis [5]. Finder's Fees - The company paid finders' fees totaling $106,662.14 in cash and issued 264,111 non-transferable compensation warrants to Ventum Financial Corp., Stephen Avenue Securities Inc., and Canaccord Genuity Corp. [2].

Core Perspective - Planet Based Foods Global Inc. (PBFG) is undergoing a fundamental transformation of its business model to become a leader in sustainable food systems and agri-tech [1][2] Business Model Transformation - The company has shifted from a focus on consumer-packaged food products to a model that integrates agriculture, technology, and sustainability to tackle food security and supply chain challenges [2] - PBFG has completed a restructuring process that includes divesting its U.S. consumer packaged goods subsidiary and returning over 1.4 million shares to treasury [3] Organizational Structure - PBFG now operates through two divisions: - PBF Tech, which focuses on climate-adaptive technologies and agri-tech solutions to enhance efficiency and resilience in food systems - PBF Trade, which aims to create sustainable supply chains by connecting producers, particularly women-led cooperatives, to global markets [4][5] Strategic Vision - The company aims to create long-term value for shareholders while positively impacting communities and the environment, emphasizing food security, climate action, and collaboration with Indigenous communities and government [6][7] Shareholder Engagement - PBFG will host a Shareholder Connection Webinar on September 16, 2025, to discuss the transformation and upcoming priorities, enhancing transparency and communication with investors [8] Company Overview - Planet Based Foods Global Inc. is focused on sustainable ingredients, plant-based solutions, and agricultural technology, promoting environmental stewardship and scalable impact in the food industry [9][10]

Core Insights - Pineapple Financial Inc. has successfully closed a private placement raising approximately $100 million, marking a significant step in its strategy to anchor its treasury in INJ, the native asset of Injective [2][3][4] - This move positions Pineapple as the first publicly traded holder of INJ, highlighting a convergence of fintech and blockchain-based finance [2][3] - The INJ treasury strategy is expected to yield around 12%, aligning with the growing trend of tokenization in the financial industry [3][4] Financial Details - The private placement involved the issuance of 24,642,700 subscription receipts, with a weighted average purchase price of approximately $4.04 per receipt [2][4] - The issuance included 7,815,777 receipts at $3.80 each and 16,826,923 receipts at $4.16 each, reflecting different terms for various purchasers [2] Market Context - The INJ asset is designed to facilitate new liquidity rails for the multi-trillion-dollar tokenization market, offering one of the highest staking yields in the industry [1][3] - The transaction attracted participation from notable investors across both traditional finance and the crypto sector, indicating strong institutional interest [4][7] Strategic Implications - Pineapple's investment in INJ is seen as a strategic alignment with the future of finance, which is expected to increasingly rely on blockchain technology for capital flows [3][6] - The company aims to leverage the speed, cost efficiency, and transparency of Injective's infrastructure to enhance its financial operations [3][6]

Core Viewpoint - Artificial Intelligence Technology Solutions, Inc. (AITX) has launched a redesigned corporate website aimed at enhancing investor and stakeholder access to company information, aligning with best practices for public companies and emphasizing transparency in communication [1][4]. Group 1: Website Launch and Features - The new website features a modernized design, improved navigation, faster performance, and advanced security, providing a better user experience for investors and stakeholders [1][3]. - The website serves as a platform for showcasing the company's vision, growth strategy, and role in the AI-driven security sector, reinforcing AITX's commitment to transparency [1][4]. Group 2: Company Operations and Market Position - AITX, through its subsidiary Robotic Assistance Devices, Inc. (RAD), is innovating within the nearly $50 billion security and guarding services industry, offering AI-driven Solutions-as-a-Service that can save businesses between 35%-80% compared to traditional manned security [5]. - RAD has a prospective sales pipeline that includes over 35 Fortune 500 companies, indicating strong potential for recurring revenue as existing sales opportunities convert into deployed clients [7]. Group 3: Technology and Compliance - AITX's technologies are developed in-house and are designed to enhance operational efficiency and reduce costs across various industries, including government, transportation, and healthcare [8]. - The company has successfully completed its SOC 2 Type 2 audit, which validates its operations and internal controls, enhancing credibility with enterprise and government clients [6].

Core Insights - LIXTE Biotechnology Holdings, Inc. is developing LB-100, the world's only clinical-stage PP2A inhibitor, which has the potential to revolutionize cancer treatment by enhancing the efficacy of existing therapies [1][11]. Group 1: Product Overview - LB-100 is a first-in-class PP2A inhibitor that disrupts cancer's internal repair systems, pushing cells into "lethal activation" and generating neoantigens to enhance immune visibility [2]. - Unlike traditional therapies, LB-100 sensitizes tumors to immunotherapy, chemotherapy, and radiation, amplifying the immune response and exposing hidden tumors [3]. Group 2: Mechanism of Action - PP2A is a crucial enzyme that regulates DNA damage repair and cell survival, often exploited by cancers to evade treatment. LB-100 disables this mechanism, preventing cancer cells from recovering from therapy-induced stress [4]. - This mechanism is particularly significant in MSS colorectal cancer (85% of cases) and ovarian clear-cell carcinoma, where current immunotherapy options are largely ineffective [5]. Group 3: Clinical Trials and Collaborations - LB-100 is currently being evaluated in multiple clinical programs, including partnerships with GSK for Ovarian Clear-Cell Carcinoma and Roche for MSS Colorectal Cancer [7][14]. - The trials aim to validate LB-100's safety and efficacy while demonstrating its role as a universal enhancer of frontline cancer therapies [10]. Group 4: Potential Impact - LB-100 has the potential to improve the tolerability and efficacy of existing therapies, reshaping treatment standards across various solid tumor indications [6]. - Enhanced activity of standard treatments and stronger immune engagement are key benefits of LB-100 [9].

Core Viewpoint - Enduro Metals Corporation has successfully closed the second and final tranche of a non-brokered private placement, raising a total of $3,621,127.58 for its exploration activities in British Columbia's Golden Triangle [1][4]. Group 1: Private Placement Details - The second tranche raised gross proceeds of $890,650.15, consisting of 289,190 flow-through shares at $0.185 each and 5,581,000 non flow-through units at $0.15 each [1][2]. - Each non flow-through unit includes one common share and one-half of a common share purchase warrant, with warrants priced at C$0.22 per share, valid until September 5, 2027 [3]. Group 2: Use of Proceeds - Proceeds from the non flow-through units will be allocated for general working capital, while funds from the flow-through shares will be used for eligible Canadian exploration expenses related to the Newmont Lake project [4]. - The company plans to renounce qualifying expenditures by December 31, 2025, and incur such expenses by December 31, 2026 [5]. Group 3: Related Transactions and Fees - The company paid finders fees totaling $4,110.01 in cash and issued 23,351 finder's warrants, which are non-transferable and exercisable at $0.18 per share until September 5, 2026 [6]. - A director of the company purchased 111,000 non flow-through units, qualifying this issuance as a related party transaction [7]. Group 4: Company Overview - Enduro Metals is focused on the Newmont Lake Project, a 688 km² property in British Columbia's Golden Triangle, with multiple deposit environments identified, including high-grade gold and copper-gold mineralization [9].

Company Overview - Mobile-health Network Solutions (MNDR) is a leading AI-powered digital healthcare platform provider headquartered in Singapore, with operations across Southeast Asia and expanding into the US [9] - Jospong Group of Companies is a diversified Ghanaian holding company with over 70 subsidiaries, operating in sectors such as waste management, banking, healthcare, insurance, logistics, and real estate [10][11] Partnership Details - MNDR and Jospong have signed a Memorandum of Understanding (MOU) to form a joint venture aimed at launching and operating MNDR's AI-powered digital health platform in Ghana [1][2] - The partnership combines MNDR's telehealth and AI-driven technology with Jospong's local market knowledge and capital resources, designed to accelerate the platform's market entry [2] Market Context - Ghana, with a population exceeding 33 million, is identified as a key market for healthcare innovation, benefiting from a similar institutional framework to other Commonwealth nations [3] - The joint venture aims to address the significant need for accessible healthcare solutions in Ghana, particularly in rural areas, by connecting patients with medical professionals through remote consultations [4] Strategic Goals - The collaboration is expected to enhance healthcare affordability, accessibility, and availability across Africa, serving as a blueprint for future regional expansion [6] - Both companies are committed to a swift and comprehensive due diligence process to finalize the joint venture agreement [6]

Core Viewpoint - ESGold Corp. has announced a brokered private placement offering to raise gross proceeds of up to C$5 million through the sale of units priced at C$0.75 each [1][2]. Group 1: Offering Details - The offering consists of up to 6,666,667 units, each unit comprising one common share and one warrant [1][2]. - Each warrant allows the holder to purchase one common share at a price of C$1.10 within 36 months following the closing date [2]. - The company has granted the agent an option to sell an additional 1,000,000 units for up to C$750,000 in gross proceeds [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for advancing the Montauban Project in Québec and for general working capital and corporate purposes [4]. Group 3: Regulatory Compliance - The offering will comply with applicable regulatory requirements and will be available to purchasers in specific Canadian provinces, the United States, and offshore jurisdictions [5]. - The securities issued will be freely tradeable in Canada if sold to Canadian residents, without a hold period [5]. Group 4: Closing and Conditions - The offering is scheduled to close on September 18, 2025, subject to necessary regulatory approvals, including that of the Canadian Securities Exchange [7]. Group 5: Company Overview - ESGold Corp. is a pre-production resource company focused on clean mining and exploration, with its flagship Montauban property located 80 kilometers west of Quebec City [10].

Core Viewpoint - GoviEx Uranium Inc. is progressing towards a reverse takeover transaction with Tombador Iron Limited, which is expected to create a new entity named "Atomic Eagle Ltd" focused on uranium development [1][2]. Transaction Details - The Arrangement Agreement was announced on August 18, 2025, and aims to simplify corporate structure and strengthen the balance sheet for the new entity [2]. - Upon completion, GoviEx shareholders will own 75% of Atomic Eagle, while Tombador shareholders will hold 25% [3]. - Tombador plans to raise between A$5.0 million and A$10.0 million at a minimum issue price of A$0.28 per share, representing a 28% premium to GoviEx's share price, which will enhance the combined company's cash reserves to between A$19.4 million and A$24.4 million [3]. Shareholder Support and Approvals - Over 40% of GoviEx securityholders have signed binding support agreements for the transaction [4][9]. - Tombador has initiated the formal approval process by filing its Meeting Circular with the Australian Securities Exchange, with a shareholder vote scheduled for October 8, 2025 [4]. - GoviEx's securityholder meeting is set for October 24, 2025, to approve the amended Arrangement Agreement [5]. Future Plans - The company intends to secure an OTC listing for Atomic Eagle alongside its ASX listing, aligning with other ASX-listed uranium peers [6]. - The transaction is expected to close in early November 2025, pending necessary approvals [6].